We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Interferon Partners with the SARI Tumor Suppressor Gene To Kill Cancer Cells

By LabMedica International staff writers
Posted on 23 Dec 2008
Cancer researchers have identified a gene regulated by interferon beta (INF-beta) that acts a tumor suppressor by inhibiting the activity of the transcription factor AP-1. More...
AP-1 (activator protein 1) is a transcription factor, which is a heterodimeric protein, composed of proteins belonging to the c-Fos, c-Jun, ATF, and JDP families. It regulates gene expression in response to a variety of stimuli, including cytokines, growth factors, stress, and bacterial and viral infections. AP-1 in turn controls a number of cellular processes including differentiation, proliferation, and apoptosis. AP-1 is overexpressed in more than 90% of human cancers, which makes it an obvious target for developers of new chemotherapeutic agents. The search for ways to modulate AP-1 led investigators at Virginia Commonwealth University (Richmond, USA) to scrutinize a gene called SARI (Suppressor of AP-1, Regulated by IFN). The investigators selected SARI because of its high level of expression in normal cells and its almost complete absence in cancer cells.

In their paper in the December 8, 2008, online edition of the journal the Proceedings of the [U.S.] National Academy of Sciences (PNAS), the investigators described using a viral vector to implant SARI into cancer cells. INF stimulation of the SARI-infected cancer cells then caused them to stop dividing and die.

"We have uncovered a new way by which interferon can induce anti-tumor activity," said senior author Dr. Paul B. Fisher, professor of human and molecular genetics at Virginia Commonwealth University. "The identification of SARI also provides a new potential reagent for the selective killing of tumor cells."

"The present study indicates that interferon can suppress cancer growth by inhibiting expression of a cancer-dependent transcription factor that controls genes that regulate cancer cell growth," said Dr. Fisher. "The SARI gene may provide novel and selective gene therapy applications for cancer. It could also prove amenable for inhibiting proliferative disorders that depend on AP-1 activity. AP-1 plays a key role in regulating proliferation and transformation of cancer cells."

Related Links:
Virginia Commonwealth University


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.